sfericase

Biologicalexperimental

Clinical trial activity

5 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Aug 31, 2015 (NCT02588521)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • al-794
  • al-794
  • sfericase

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05317078Phase 1Dec 31, 2022Amgen
NCT03411421Phase 1Mar 3, 2018Alios BioPharma, Hammersmith Medicines Research
NCT02888327Phase 1Jul 31, 2016Alios BioPharma, Hammersmith Medicines Research
NCT02877160Phase 1Jun 30, 2016Alios BioPharma
NCT02588521Phase 1Aug 31, 2015Alios BioPharma
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Alios BioPharmaFor profit4412015
Hammersmith Medicines ResearchFor profit2012016
AmgenFor profit1112022
3 organizations
Page 1 / 1